**CASE REPORT**

Contrast-Induced Encephalopathy after Coil Embolization: A Case Report and Review of Literature

Yuwhan Chung, Jiwook Ryu, Eui Jong Kim

Departments of 1Neurosurgery, 2Radiology, KyungHee University College of Medicine, Seoul, Republic of Korea

Contrast-induced encephalopathy (CIE) is a rare and unexpected complication after coil embolization for the treatment of cerebral aneurysm. A 66-year-old woman underwent secondary coil embolization with iodixanol for recanalization of the left middle cerebral artery aneurysm. Preoperative computed tomography revealed encephalomalacia in the left frontal and temporal lobe caused by previous aneurysmal rupture. Two hours after the procedure, the patient showed status epilepticus and right hemiplegia. Fluid-attenuated inversion recovery imaging revealed extensive involvement of CIE in the left hemisphere. CIE-related symptoms gradually resolved with conservative treatment including antiepileptic drugs, mannitol, and methylprednisolone. Two-month follow-up magnetic resonance imaging revealed that the edema markedly improved in the parietal area but remained in the frontal area, and the patient completely recovered without any sequelae. Even iodixanol, which is an iso-osmolar contrast medium, could lead to CIE manifesting as a serious condition such as status epilepticus. Endovascular neurosurgeons should always be aware of CIE, especially when encephalomalacia is present.

**Key Words:** Contrast-induced encephalopathy, Encephalomalacia, Status epilepticus

INTRODUCTION

Contrast-induced encephalopathy (CIE) is an unexpected neurological complication after endovascular procedures with contrast media.\(^1^,^2\) This complication has a rare incidence that broadly ranges from 0.3% to 1% but might increase to 4% when a hyperosmolar contrast is used.\(^11^\) Its clinical presentations are mainly characterized by transient cortical blindness, headache, memory loss, hemiparesis, aphasia, loss of coordination, confusion, seizures, and coma.\(^13^\) A convincing theory of CIE is that hyperosmolar contrast agents remove fluid from the endothelial cells, causing them to disrupt the tight junctions of blood-brain barrier.\(^1^,^5^\)

Iodixanol, which is the only iso-osmolar contrast medium, has a more favorable neurotoxicity profile than that of monomeric, nonionic contrast media.\(^1^,^1^4^\) The association between CIE and iodixanol contrast agents has rarely been reported.\(^2,^1^0^\) Here, we report CIE where despite the use of iodixanol, the patient developed serious complications such as status epilepticus and hemiplegia after secondary coiling. The potential predisposing risk factors are also discussed.

CASE REPORT

A 66-year-old woman was admitted for the treatment of recanalization of a left middle cerebral artery (MCA) aneurysm. Ten years earlier, she underwent surgical clipping of an incidentally discovered MCA unruptured aneurysm. However, one year earlier, she presented with subarachnoid hemorrhage following the rupture of the previously clipped MCA aneurysm (Figure 1A) and underwent stent-assisted coiling at another hospital. The procedure was performed using 150 ml of iopromide (Ultravist®, Bayer, NJ, United States) without adverse reaction to the contrast medium used.

Follow-up brain computed tomography (CT) revealed encephalomalacic change in the left frontal and temporal lobe caused by aneurysmal rupture (Figure 1B and 1C). Cerebral angiography was performed using 100 ml of iodixanol (Visipaque 270, GE Healthcare, Princeton, NJ, USA) without any complications and revealed the major recanalization of previously coiled aneurysm (Figure 1D and 1E). The coil embolization procedure was performed via the right transfemoral approach. A guidewire was inserted into the left internal carotid artery (ICA) and extended to the tortuous carotid artery. Subsequently, 6-Fr guiding catheters (Asahi Fubuki®; Asahi Intecc Co., Ltd., Aichi, Japan) were placed in the left ICA, and a microcatheter (SL 10, Stryker Neurovascular, CA, USA) and microwire (Traxcess, Microvention, CA, USA) were placed in the aneurysm sac through the strut of the previous stent (trans-cell technique). The aneurysm was completely obliterated with six coils (Axium Prime, Medtronic, Minnesota, USA), maintaining the distal MCA arterial flow. A total of 250 ml of iodixanol was used during the procedure. There was no thromboembolic event during the procedure. She recovered from anesthesia without any complications. However, the patient’s postoperative brain CT revealed contrast enhancement and gyral effacement, indicating cerebral edema in the left hemisphere (Figure 2A).

**Received:** December 18, 2020  
**Revised:** February 04, 2021  
**Accepted:** March 02, 2021
Two hours after the procedure, the patient developed sudden-onset right-sided hemiplegia and aphasia. She gradually became more lethargic and finally developed generalized tonic-clonic seizures for 5 min. Although intravenous lorazepam (4 mg) was administered repeatedly, the seizures did not stop and even prolonged for more than 30 min. She was administered 1000-mg phenytoin sodium followed by 1000-mg sodium valproate with no respite in seizures. She was considered to be experiencing refractory status epilepticus and moved to the intensive care unit for therapeutic coma induction. Seizure control was achieved at a dose of 2 mg/kg/h of propofol. Under high suspicion of postoperative stroke, a follow-up cerebral angiogram and diffusion-weighted imaging were performed, but

---

Table 1. Reported cases of contrast-induced encephalopathy after coil embolization

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Case no.</th>
<th>Sex/age</th>
<th>SAH/URA</th>
<th>Aneurysm site</th>
<th>Onset time</th>
<th>Symptoms</th>
<th>Volume of contrast (ml)</th>
<th>Contrast agent</th>
<th>Side of guiding catheter</th>
<th>Extent of CIE</th>
<th>T2 high SI lesion</th>
<th>Clinical resolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uchiyama et al. 2003</td>
<td>1</td>
<td>M/72</td>
<td>SAH</td>
<td>Acom</td>
<td>1 hour</td>
<td>Hemiparesis, motor aphasia and sensory loss, right-sided neglect</td>
<td>260</td>
<td>Iopamidol</td>
<td>Left ICA</td>
<td>Left cerebral hemisphere</td>
<td>NA</td>
<td>1 week</td>
</tr>
<tr>
<td>Leong et al. 2012</td>
<td>2</td>
<td>F/50</td>
<td>URA</td>
<td>ICA</td>
<td>Immediate</td>
<td>Hemiparesis, aphasia, and sensory loss</td>
<td>220</td>
<td>Iopromide</td>
<td>NA</td>
<td>Left cerebral hemisphere</td>
<td>Present</td>
<td>1 year</td>
</tr>
<tr>
<td>Nagamine et al. 2014</td>
<td>3</td>
<td>F/58</td>
<td>URA</td>
<td>ICA</td>
<td>4 weeks</td>
<td>Hemiparesis, aphasia, and sensory loss</td>
<td>316</td>
<td>Iohexol</td>
<td>Left ICA</td>
<td>Left fronto-parieto-occipital</td>
<td>Present</td>
<td>50 days</td>
</tr>
<tr>
<td>Matsubara et al. 2017</td>
<td>4</td>
<td>F/63</td>
<td>URA</td>
<td>Acom</td>
<td>Immediate</td>
<td>Hemiparesis</td>
<td>210</td>
<td>Iodixanol</td>
<td>Left ICA</td>
<td>Bilateral frontal</td>
<td>NA</td>
<td>1 month</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>F/51</td>
<td>URA</td>
<td>ICA</td>
<td>Several hours</td>
<td>Visual disturbance</td>
<td>270</td>
<td>Iopamidol</td>
<td>Left VA</td>
<td>Bilateral occipital</td>
<td>NA</td>
<td>1 week</td>
</tr>
<tr>
<td>Onishi et al. 2018</td>
<td>6</td>
<td>F/67</td>
<td>URA</td>
<td>IC-PC and ACA</td>
<td>30 min</td>
<td>Hemiparesis, aphasia, and sensory loss</td>
<td>NA</td>
<td>NA</td>
<td>Left ICA</td>
<td>Left cerebral hemisphere</td>
<td>NA</td>
<td>1 day</td>
</tr>
<tr>
<td>Our case</td>
<td>7</td>
<td>F/66</td>
<td>SAH</td>
<td>MCA bifurcation</td>
<td>2 hours</td>
<td>Status epilepticus, hemiplegia</td>
<td>250</td>
<td>Iohexol</td>
<td>Left ICA</td>
<td>Left fronto-temporal</td>
<td>Present</td>
<td>2 months</td>
</tr>
</tbody>
</table>

*AC/A, anterior choroidal artery; Acom, anterior communicating artery; CIE, contrast-induced encephalopathy; ICA, internal carotid artery; IC-PC, internal carotid-posterior communicating artery; SAH, subarachnoid hemorrhage; SI, signal intensity; URA, unruptured aneurysm; VA, vertebral artery
they revealed patent MCA flow without cerebral infarction (Figure 2B and 2C). Electroencephalography demonstrated repetitive sharp waves concentrated in the left frontotemporoparietal area (Figure 2D). Hydration and intravenous administration of methylprednisolone, mannitol, and anticonvulsant agent were also provided for symptom control. Propofol tapering was attempted after 72 hours of seizure-free period.

Recovery (with spontaneous eye opening) started to occur on postoperative day 7, and the hemiplegia gradually resolved. T2-weighted images demonstrated extensive cerebral edema of the left frontotemporoparietal area (Figure 3A and 3B). Two-month follow-up magnetic resonance imaging (MRI) revealed that the edema markedly improved in the parietal area but remained in the frontal area (Figure 3C and 3D). Finally, the patient completely recovered without any neurologic sequelae.

**DISCUSSION**

Since 2010, there has been an increasing trend on the incidence of CIE (Table 1). To the best of our knowledge, there has been only one case that reports CIE after coil embolization using ioxaglate contrast medium.

The clinical presentation of CIE can sometimes mimic acute stroke, but imaging findings present several characteristics of CIE. The most common symptoms of CIE include cortical blindness, headache, vomiting, agitation, hemiplegia, seizures, confusion, transient global amnesia, and dysarthria-aphasia. Cerebral angiography and diffuse-weighted imaging were also performed because of high clinical suspicion for postoperative acute ischemic stroke. Radiologic findings of CIE are characterized, consistent with our case, by gyral swelling and hyperintensity on T2 image on MRI and also abnormal cortical contrast enhancement, edema, and subarachnoid contrast enhancement on CT. Thus, it is important to differentiate between CIE and stroke as promptly and accurately as possible.

Possible risk factors for CIE include chronic hypertension (HTN) with impaired cerebral autoregulation, chronic kidney disease, and a large volume of contrast media. This patient had a history of chronic HTN, previous SAH, and the large amount of contrast (250 ml) administration for repeat arteriograms. Additionally, given the evidence of long-standing persistent T2 high signal of the left frontal lobe in the late stage of CIE, the presence of precedent encephalomalacia may have predisposed the patients to CIE and facilitated the contrast agent to disrupt the blood-brain barrier, causing cerebral edema.

It is unclear whether the difference in types and doses of the contrast media develops CIE. Theoretically, ioxaglate, which is an isosmolar contrast agent, hardly induces blood-brain barrier damage, and it has been associated with fewer adverse effects and only rarely with CIE. A comparison study showed both ioxaglate and iopromide to be safe, effective, and well tolerated. CIE also developed during angiography procedure with contrast volumes less than 40 mL and even with 25 mL of contrast media for local injection into the carotid artery. In our case, CIE did not develop during cerebral angiography with 100 mL of ioxaglate but during coil embolization with 250 mL of ioxaglate. Thus, ioxaglate-induced encephalopathy appears to be an idiosyncratic reaction.

There is no definite treatment strategy of CIE given the unexpected and rare nature of the complication. Previous reports demonstrated that hydration and intravenous steroid and mannitol administration may be helpful for symptom control. Although the prognosis of CIE has been benign with a wait-and-see approach in most reported cases, CIE could present with severe neurological symptoms, and permanent neurological symptoms may remain.

**CONCLUSION**

Despite the use of ioxaglate contrast media, CIE can develop during coil embolization. Endovascular neurosurgeons should always be aware of CIE, especially when encephalomalacia is present.

**Informed Consent:**

Informed consent was obtained from all individual participants included in the study.
REFERENCES